Jefferies Starts ANI Pharmaceuticals (ANIP) at Buy

Jefferies analyst Glen Santangelo initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Buy rating and a price target of $80.00.

The analyst comments: "We expect cont momentum driven primarily by Cortrophin Gel & Generics w the setup relative to expectations favorable, esp in 1Q. W valuation at a pure-play gx multiple (7x EBITDA), we believe investors underappreciate the transition towards branded rare disease products & the impact it is having on growth and margin. W key segments set to grow faster than exp in 2025, we see potl for multiple expansion that reflects the 50/50 brand/gx mix. Initiate Buy, $80 PT."

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $61.46 yesterday.

You May Also Be Interested In

• Tractor Supply Company (TSCO) PT Lowered to $33 at UBS
• UBS Reiterates Buy Rating on United Airlines (UAL) Ahead of Q2 Results
• NVIDIA, Mitsubishi Heavy Industries eye cooperation on AI data center cooling and power - Nikkei